

# Inventor Search

KRISHNAN 09/923,023

=> d his

(FILE 'HOME' ENTERED AT 17:07:31 ON 10 OCT 2003)

FILE 'HCAPLUS' ENTERED AT 17:07:41 ON 10 OCT 2003

L1 75 S COLACO C7/AU  
L2 6 S L1 AND GLYCOSID?  
SELECT RN 1 2 6 L2

FILE 'REGISTRY' ENTERED AT 17:10:34 ON 10 OCT 2003

L3 69 S E1-69

FILE 'HCAPLUS' ENTERED AT 17:11:03 ON 10 OCT 2003

L4 3 S L2 AND L3

*3 cites w/ 69 cpts displayed*

=> d ibib abs hitstr ind 1-3

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:48730 HCAPLUS  
DOCUMENT NUMBER: 130:129975  
TITLE: Modified glycosides and compositions  
comprised thereof for medical and other uses  
INVENTOR(S): Colaco, Camilo  
PATENT ASSIGNEE(S): Quadrant Holdings Cambridge Limited, UK  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901463	A2	19990114	WO 1998-GB1962	19980703
WO 9901463	A3	19990325		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
EP 994887	A2	20000426	EP 1998-932361	19980703
EP 994887	B1	20021127		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002510316	T2	20020402	JP 1999-506677	19980703
AT 228528	E	20021215	AT 1998-932361	19980703
ES 2187038	T3	20030516	ES 1998-932361	19980703
US 2002009464	A1	20020124	US 2001-923023	20010806
PRIORITY APPLN. INFO.:			US 1997-51727P	P 19970703
			WO 1998-GB1962	W 19980703
			US 1998-111925	A1 19980708

AB Modified glycosides YnX (Y = saccharide subunit; X = C5-6 sugar alc.; n = 1-6; part or all of the OH groups in X and Y are derivatized as esters or ethers) are provided which can be used to form a variety of materials including biodegradable solid delivery systems and optically clear colored devices or coatings. The solid delivery systems can be used for delivery and release of a variety of substances including lipids, proteins, peptides, peptidomimetics, hormones, saccharides, nucleic acids, and nucleoproteins, as well as viruses, bacteria, antigens, and haptens coupled to carriers; they can be in the form of tablets for oral administration, or in the form of powders, microspheres or implants for i.v., intradermal, transdermal, pulmonary, or other route of administration. The modified glycosides may be processed to form a vitreous glass matrix having a substance, such as a therapeutic

agent, or an optically active dye incorporated therein. The vitreous glass matrix may be provided in a solid dosage form which is capable of releasing a therapeutic substance in situ at various controlled rates. Alternatively, a melt or soln. contg. modified glycosides and a dye can be used to produce optically clear colored coatings, plastic articles, and synthetic fibers. Thus, nonaacylated derivs. of lactitol, palatinit, .alpha.-D-glucopyranosyl-(1.fwdarw.6)-sorbitol, and .alpha.-D-glucopyranosyl-(1.fwdarw.6)-mannitol with a range of m.p. values and glass transition temps. were produced by reaction of the polyols with Ac2O. Glasses produced by quenching melts of the acetylated polyols were good solvents for poorly water-sol. solutes such as Disperse Red 1; the solutes had little effect on the glass transition temp. and did not cause devitrification. Lactitol nonaacetate glasses contg. cyclosporin A and diltiazem-HCl showed different profiles of controlled release on immersion in saline soln.; the release rates were altered by addn. of Tween 20 to the soln.

- IT 33286-22-5, Diltiazem hydrochloride 59865-13-3,  
Cyclosporin A  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modified glycosides and compns. comprised thereof for medical and other uses)
- RN 33286-22-5 HCAPLUS
- CN 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl


- RN 59865-13-3 HCAPLUS
- CN Cyclosporin A (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




PAGE 1-A

PAGE 1-B




PAGE 1-C



IT 9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified glycosides and compns. comprised thereof for medical and other uses)  
 RN 9002-72-6 HCAPLUS  
 CN Somatotropin (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 RN 9004-10-8 HCAPLUS  
 CN Insulin (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 IT 37091-07-9P, Lactitol nonaacetate 41897-24-9P, Maltitol nonaacetate 41897-25-0P 219827-68-6P 219827-69-7P  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (modified glycosides and compns. comprised thereof for medical and other uses)  
 RN 37091-07-9 HCAPLUS  
 CN D-Glucitol, 4-O-(2,3,4,6-tetra-O-acetyl-.beta.-D-galactopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)



RN 41897-24-9 HCAPLUS


CN D-Glucitol, 4-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)



RN 41897-25-0 HCAPLUS

CN D-Glucitol, 6-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219827-68-6 HCAPLUS

CN D-Mannitol, 1-O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219827-69-7 HCAPLUS


CN D-Glucitol, 6-O-(2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl)-, pentaacetate, mixt. with 1-O-(2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl)[D-mannitol] pentaacetate (9CI) (CA INDEX NAME)

CM 1

CRN 219827-68-6

CMF C30 H42 O20

Absolute stereochemistry.




CM 2

CRN 41897-25-0

CMF C30 H42 O20

Absolute stereochemistry.




IT 50-70-4P, D-Glucitol, biological studies 69-65-8P, D-Mannitol 87-99-0P, Xylitol 149-32-6P, Erythritol 488-81-3P, Ribitol 608-66-2P, Galactitol  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modified glycosides contg.; modified glycosides and compns. comprised thereof for medical and other uses)

RN 50-70-4 HCAPLUS

CN D-Glucitol (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 69-65-8 HCAPLUS

CN D-Mannitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 87-99-0 HCAPLUS  
CN Xylitol (6CI, 8CI, 9CI) (CA INDEX NAME)




RN 149-32-6 HCAPLUS  
CN 1,2,3,4-Butanetetrol, (2R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 488-81-3 HCAPLUS  
CN Ribitol (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 608-66-2 HCAPLUS  
CN Galactitol (6CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 50-69-1P, D-Ribose 50-99-7P, D-Glucose, biological studies 57-48-7P, D-Fructose, biological studies 58-86-6P, D-Xylose, biological studies 59-23-4P, D-Galactose, biological studies 65-42-9P, Lyxose 147-81-9P, Arabinose 3458-28-4P, D-Mannose 5556-48-9P, Ribulose 5987-68-8P, Altrose 6038-51-3P, Allose 19163-87-2P, Gulose  
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modified polyol glycosides contg.; modified glycosides and compns. comprised thereof for medical and other uses)


RN 50-69-1 HCAPLUS  
CN D-Ribose (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 50-99-7 HCAPLUS  
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-48-7 HCAPLUS  
CN D-Fructose (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 58-86-6 HCAPLUS  
CN D-Xylose (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 59-23-4 HCAPLUS  
CN D-Galactose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 65-42-9 HCAPLUS  
CN Lyxose (6CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 147-81-9 HCAPLUS  
CN Arabinose (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 3458-28-4 HCAPLUS  
CN D-Mannose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 5556-48-9 HCAPLUS  
CN erythro-2-Pentulose (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 5987-68-8 HCAPLUS  
CN Allose (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 6038-51-3 HCAPLUS  
CN Allose (6CI, 8CI, 9CI) (CA INDEX NAME)


Relative stereochemistry.






RN 19163-87-2 HCAPLUS  
 CN Gulose (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 2872-52-8, Disperse Red 1  
 RL: PRP (Properties)  
 (soly. in modified glycoside glass; modified glycosides and compns. comprised thereof for medical and other uses)

RN 2872-52-8 HCAPLUS  
 CN Ethanol, 2-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]- (9CI) (CA INDEX NAME)



IC ICM C07H  
 CC 63-6 (Pharmaceuticals)  
 ST glycoside modified glass drug delivery; coating modified glycoside glass dye  
 IT Immunostimulants  
 (adjuvants; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Haptens  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (conjugates with carriers; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Drug delivery systems  
 (controlled-release, solid; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Drug delivery systems  
 (disks; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Glycosides  
 Oligosaccharides, biological studies  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (esters and ethers; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Drug delivery systems  
 (films; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Drug delivery systems  
 (implants; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Drug delivery systems  
 (lozenges; modified glycosides and compns. comprised thereof for medical and other uses)  
 IT Glass fibers, biological studies  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU

- (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (microfibers; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Drug delivery systems  
 (microparticles; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Drug delivery systems  
 (microspheres; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Animal virus  
 Bacteria (Eubacteria)  
 Drug delivery systems  
 Dyes  
 Genetic vectors  
 Glass transition temperature  
 Needles (tools)  
 Optical filters  
 Peptidomimetics  
 Transparent materials  
 Vitreous materials  
 (modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Antigens  
 Carbohydrates, biological studies  
 Cytokines  
 Enzymes, biological studies  
 Growth factors, animal  
 Hormones, animal, biological studies  
 Interferons  
 Interleukins  
 Lipids, biological studies  
 Nucleic acids  
 Nucleoproteins  
 Peptides, biological studies  
 Proteins, general, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Isomaltooligosaccharides  
 Maltooligosaccharides  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (modified polyol **glycosides** contg.; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Antibodies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (monoclonal; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Acetylation  
 (of **glycosides**; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Quenching (cooling)  
 (of modified **glycoside** melts; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Solutions  
 (of modified **glycosides**, glass formation from; modified **glycosides** and compns. comprised thereof for medical and other uses)
- IT Drug delivery systems  
 (particles; modified **glycosides** and compns. comprised thereof

- for medical and other uses)
- IT Alcohols, biological studies  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (polyhydric, glycosides, esters and ethers; modified glycosides and compns. comprised thereof for medical and other uses)
- IT Drug delivery systems  
 (powders; modified glycosides and compns. comprised thereof for medical and other uses)
- IT Drug delivery systems  
 (spheres; modified glycosides and compns. comprised thereof for medical and other uses)
- IT Drug delivery systems  
 (suppositories; modified glycosides and compns. comprised thereof for medical and other uses)
- IT Drug delivery systems  
 (tablets; modified glycosides and compns. comprised thereof for medical and other uses)
- IT Metals, uses  
 Plastics, uses  
 RL: DEV (Device component use); USES (Uses)  
 (transparent coatings on; modified glycosides and compns. comprised thereof for medical and other uses)
- IT Coating materials  
 (transparent; modified glycosides and compns. comprised thereof for medical and other uses)
- IT 33286-22-5, Diltiazem hydrochloride 59865-13-3, Cyclosporin A  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified glycosides and compns. comprised thereof for medical and other uses)
- IT 9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (modified glycosides and compns. comprised thereof for medical and other uses)
- IT 37091-07-9P, Lactitol nonaacetate 41897-24-9P, Maltitol nonaacetate 41897-25-0P 219827-68-6P 219827-69-7P  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (modified glycosides and compns. comprised thereof for medical and other uses)
- IT 50-70-4P, D-Glucitol, biological studies 69-65-8P, D-Mannitol 87-99-0P, Xylitol 149-32-6P, Erythritol 488-81-3P, Ribitol 608-66-2P, Galactitol  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (modified glycosides contg.; modified glycosides and compns. comprised thereof for medical and other uses)
- IT 50-69-1P, D-Ribose 50-99-7P, D-Glucose, biological studies 57-48-7P, D-Fructose, biological studies 58-86-6P, D-Xylose, biological studies 59-23-4P, D-Galactose, biological studies 65-42-9P, Lyxose 147-81-9P, Arabinose 3458-28-4P, D-Mannose 5556-48-9P, Ribulose 5987-68-8P, Altrose 6038-51-3P, Allose 19163-87-2P, Gulose  
 RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

## (Uses)

(modified polyol glycosides contg.; modified glycosides and compns. comprised thereof for medical and other uses)

IT 2872-52-8, Disperse Red 1

RL: PRP (Properties)

(soly. in modified glycoside glass; modified glycosides and compns. comprised thereof for medical and other uses)

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1996:336393 HCAPLUS

DOCUMENT NUMBER: 125:19009

TITLE: Solid delivery systems for controlled release of molecules incorporated therein

INVENTOR(S): Roser, Bruce Joseph; Colaco, Camilo; Jerrow, Mohamed Abdel Zahra; Blair, Julian Alexander; Kampinga, Jaap; Wardell, James Lewis; Duffy, John Alistair

PATENT ASSIGNEE(S): Quadrant Holdings Cambridge Limited, UK

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603978	A1	19960215	WO 1995-GB1861	19950804
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6290991	B1	20010918	US 1994-349029	19941202
CA 2197982	AA	19960215	CA 1995-2197982	19950804
AU 9531851	A1	19960304	AU 1995-31851	19950804
AU 688557	B2	19980312		
EP 773781	A1	19970521	EP 1995-927856	19950804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10503769	T2	19980407	JP 1995-506345	19950804
HU 77777	A2	19980828	HU 1998-694	19950804
CN 1204959	A	19990113	CN 1995-195496	19950804
EP 1138319	A2	20011004	EP 2001-116637	19950804
EP 1138319	A3	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
EP 1138337	A2	20011004	EP 2001-116638	19950804
EP 1138337	A3	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
RU 2177785	C2	20020110	RU 1997-103529	19950804
EE 3593	B1	20020215	EE 1997-62	19950804
PL 184068	B1	20020830	PL 1995-318898	19950804
SK 283026	B6	20030204	SK 1997-277	19950804
FI 9700867	A	19970408	FI 1997-867	19970228
NO 9701688	A	19970411	NO 1997-1688	19970411
AU 9871864	A1	19980820	AU 1998-71864	19980612
AU 707605	B2	19990715		
US 6331310	B1	20011218	US 2000-628380	20000801
US 2001038858	A1	20011108	US 2001-755737	20010105
US 6586006	B2	20030701		
US 2002012687	A1	20020131	US 2001-945180	20010831
US 6565871	B2	20030520		

US 2003054040	A1	20030320	US 2002-280468	20021025
US 2003147961	A1	20030807	US 2003-376136	20030227
PRIORITY APPLN. INFO.:			GB 1994-15810	A 19940804
			US 1994-349029	A 19941202
			EP 1995-927856	A3 19950804
			WO 1995-GB1861	W 19950804
			US 1997-500877	B1 19970818
			US 2000-628380	A1 20000801
			US 2001-945180	A1 20010831


AB Solid dosage delivery systems suitable for delivery of bioactive materials s.c., intradermal, i.m., and i.v. are disclosed. The delivery systems comprise a vitreous vehicle, e.g. polyol, loaded with the guest substance and capable of releasing the guest substance in situ at various controlled rates. Microparticles were prep'd. by spray drying a soln. of 0.39 M trehalose, 0.14 M calcium lactate and 0.5% MB9. This particles were coated by addn. of a satd. soln. of zinc palmitate in toluene and cooling at 60-30.degree.. The particles were then filtered under vacuum to remove excess zinc palmitate, washed with acetone, and air-dried. The resulting powder remained unwetted in water for .gtoreq. 3 days and released MB9 slowly into the water.

IT 50-99-7, Glucose, biological studies 57-50-1, biological studies 57-83-0, Progesterone, biological studies 58-22-0, Testosterone 63-42-3 69-79-4 99-20-7, Trehalose 470-55-3 512-69-6 585-86-4, Lactitol 585-88-6, Maltitol 597-12-6, Melezitose 604-68-2, .alpha.-D-Glucose pentaacetate 604-69-3, .beta.-D-Glucose pentaacetate 3616-19-1, Cellobiose octaacetate 4618-18-2, Lactulose 6424-12-0, Raffinose undecaacetate 6556-12-3D, Glucuronic acid, polymers 7208-47-1, Sorbitol hexaacetate 9003-99-0, Peroxidase 9004-10-8, Insulin, biological studies 9004-54-0, Dextran, biological studies 13718-94-0, Isomaltulose 17273-84-6, Aluminum hexanoate 17606-72-3, Maltulose 20942-99-8 25018-27-3, Trehalose octaacetate 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26680-10-4, Polylactide 26780-50-7, Poly(glycolide-lactide) 27253-33-4, Calcium neodecanoate 38954-67-5 59865-13-3, Cyclosporin a 64519-82-0, Palatinit 66112-59-2, Saf-1 66594-14-7, Quil a 102787-20-2 177327-93-4 177327-94-5 177472-68-3  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled-release solid delivery systems comprising polyols)

RN 50-99-7 HCAPLUS

CN D-Glucose (8CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 57-50-1 HCAPLUS


CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-83-0 HCAPLUS  
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 58-22-0 HCAPLUS  
CN Androst-4-en-3-one, 17-hydroxy-, (17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 63-42-3 HCAPLUS  
CN D-Glucose, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 69-79-4 HCAPLUS  
CN D-Glucose, 4-O-.alpha.-D-glucopyranosyl- (6CI, 9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 99-20-7 HCAPLUS

CN .alpha.-D-Glucopyranoside, .alpha.-D-glucopyranosyl (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 470-55-3 HCAPLUS

CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH

RN 512-69-6 HCAPLUS

CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 585-86-4 HCAPLUS

CN D-Glucitol, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 585-88-6 HCAPLUS

CN D-Glucitol, 4-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 597-12-6 HCAPLUS

CN .alpha.-D-Glucopyranoside, O-.alpha.-D-glucopyranosyl-(1.fwdarw.3)-.beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 604-68-2 HCAPLUS

CN .alpha.-D-Glucopyranose, pentaacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 604-69-3 HCAPLUS

CN .beta.-D-Glucopyranose, pentaacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 3616-19-1 HCAPLUS

CN D-Glucopyranose, 4-O-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranosyl)-, tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 4618-18-2 HCAPLUS

CN D-Fructose, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6424-12-0 HCAPLUS

CN .alpha.-D-Glucopyranoside, 1,3,4,6-tetra-O-acetyl-.beta.-D-fructofuranosyl  
0-2,3,4,6-tetra-O-acetyl-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-,  
triacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 6556-12-3 HCAPLUS

CN D-Glucuronic acid (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 7208-47-1 HCAPLUS

CN D-Glucitol, hexaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9003-99-0 HCAPLUS

CN Peroxidase (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 9004-10-8 HCAPLUS

CN Insulin (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 9004-54-0 HCAPLUS


CN Dextran (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 13718-94-0 HCAPLUS

CN D-Fructose, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17273-84-6 HCAPLUS

CN Hexanoic acid, aluminum salt (8CI, 9CI) (CA INDEX NAME)


Me-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H

●1/3 A1

RN 17606-72-3 HCAPLUS

CN D-Fructose, 4-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 20942-99-8 HCAPLUS

CN D-Mannitol, 1-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 25018-27-3 HCAPLUS


CN .alpha.-D-Glucopyranoside, 2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26023-30-3 HCAPLUS

CN Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] (8CI, 9CI) (CA INDEX NAME)




RN 26680-10-4 HCAPLUS

CN 1,4-Dioxane-2,5-dione, 3,6-dimethyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 95-96-5

CMF C6 H8 O4




RN 26780-50-7 HCAPLUS

CN 1,4-Dioxane-2,5-dione, 3,6-dimethyl-, polymer with 1,4-dioxane-2,5-dione (9CI) (CA INDEX NAME)

CM 1


CRN 502-97-6

CMF C4 H4 O4




CM 2

CRN 95-96-5  
CMF C6 H8 O4




RN 27253-33-4 HCAPLUS  
CN Neodecanoic acid, calcium salt (9CI) (CA INDEX NAME)



●1/2 Ca

RN 38954-67-5 HCAPLUS  
CN .beta.-D-Glucopyranoside, octyl, tetraacetate (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 59865-13-3 HCAPLUS  
CN Cyclosporin A (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 64519-82-0 HCAPLUS


CN D-Glucitol, 6-O-.alpha.-D-glucopyranosyl-, mixt. with 1-O-.alpha.-D-glucopyranosyl-D-mannitol (9CI) (CA INDEX NAME)

CM 1

CRN 20942-99-8

CMF C12 H24 O11


Absolute stereochemistry.



CM 2


CRN 534-73-6  
CMF C12 H24 011

Absolute stereochemistry.



RN 66112-59-2 HCAPLUS  
CN D-.alpha.-Glutamine, N-(N-acetylmuramoyl)-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 66594-14-7 HCAPLUS  
CN Quil-A (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 102787-20-2 HCAPLUS  
CN .alpha.-D-Glucopyranoside, 1,3,4,6-tetrakis-O-(1-oxopropyl)-.beta.-D-fructofuranosyl, tetrapropionate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177327-93-4 HCAPLUS

CN .alpha.-D-Glucopyranoside, 2,3,4,6-tetrakis-O-(1-oxopropyl)-.alpha.-D-glucopyranosyl, tetrapropanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 177327-94-5 HCAPLUS

CN .alpha.-D-Glucopyranoside, 1,3,4,6-tetrakis-O-(1-oxopropyl)-.beta.-D-fructofuranosyl 0-2,3,4,6-tetrakis-O-(1-oxopropyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-, tripropanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A



RN 177472-68-3 HCAPLUS

CN .beta.-D-Glucopyranose, 4-O-[2,3,4,6-tetrakis-O-(1-oxopropyl)-.beta.-D-glucopyranosyl]-, tetrapropionate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K009-16

ICS A61K009-22

CC 63-6 (Pharmaceuticals)

ST controlled release solid delivery system polyol; microparticle MB9 lactate trehalose

IT Albumins, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bovine; controlled-release solid delivery systems comprising polyols)

IT Animal cell

Bacteria

Measles  
 Molecules  
 Mumps  
 Poliomyelitis  
 Rubella  
 Shigella  
 Streptococcus pneumoniae  
 Tuberculosis  
 Vaccines  
 Virus  
 Yellow fever

(controlled-release solid delivery systems comprising polyols)

IT Analgesics  
 Animal growth regulators  
 Antibiotics  
 Antibodies  
 Anticoagulants and Antithrombotics  
 Antidepressants  
 Antiemetics  
 Antigens  
 Antihistaminics  
 Antihypertensives  
 Anxiolytics  
 Appetite depressants  
 Campylobacter pyloridis  
 Carbohydrates and Sugars, biological studies  
 Cardiovascular agents  
 Cholera  
 Cholinergic agonists  
 Cholinergic antagonists  
 Contraceptives  
 Dengue  
 Deoxyribonucleic acids  
 Diphtheria  
 Diuretics  
 Estrogens  
 Haptens  
 Hormones  
 Immunostimulants  
 Immunosuppressants  
 Inflammation inhibitors  
 Influenza  
 Interferons  
 Lipids, biological studies  
 Lymphokines and Cytokines  
 Mitogens  
 Muscle relaxants  
 Mycolic acids  
 Narcotic antagonists  
 Nitrates, biological studies  
 Nucleic acids  
 Nucleotides, biological studies  
 Oligosaccharides  
 Opioids  
 Organic matter  
 Peptides, biological studies  
 Phosphazene polymers  
 Phycoerythrins  
 Polyanhydrides  
 Polyesters, biological studies  
 Polysaccharides, biological studies  
 Proteins, biological studies  
 Ribonucleic acids  
 Saponins  
 Steroids, biological studies  
 Sulfates, biological studies  
 Tetanus

Tranquilizers and Neuroleptics  
 Virucides and Virustats  
 Whooping cough  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (controlled-release solid delivery systems comprising polyols)  
 IT Pharmaceutical dosage forms  
 (fibers; controlled-release solid delivery systems comprising polyols)  
 IT Fissurella  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hemocyanins; controlled-release solid delivery systems comprising polyols)  
 IT Maillard reaction  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitors; controlled-release solid delivery systems comprising polyols)  
 IT Glycosides  
 Parkinsonism  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (mono-reducing; controlled-release solid delivery systems comprising polyols)  
 IT Hepatitis  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (A, controlled-release solid delivery systems comprising polyols)  
 IT Hepatitis  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C, controlled-release solid delivery systems comprising polyols)  
 IT Hepatitis  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (E, controlled-release solid delivery systems comprising polyols)  
 IT Virus, animal  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Japanese encephalitis, controlled-release solid delivery systems comprising polyols)  
 IT Immunostimulants  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (adjuvants, controlled-release solid delivery systems comprising polyols)  
 IT Immunostimulants  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (adjuvants, Freund's, controlled-release solid delivery systems comprising polyols)  
 IT Carbohydrates and Sugars, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (alditols, controlled-release solid delivery systems comprising polyols)  
 IT Inflammation inhibitors  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antiarthritics, controlled-release solid delivery systems comprising polyols)  
 IT Tranquilizers and Neuroleptics  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antipsychotics, controlled-release solid delivery systems comprising polyols)  
 IT Vasodilators  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (cerebral, controlled-release solid delivery systems comprising polyols)  
 IT Therapeutics  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (chemo-, controlled-release solid delivery systems comprising polyols)  
 IT Toxins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (cholera, b subunit; controlled-release solid delivery systems comprising polyols)  
 IT Vasodilators  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (coronary, controlled-release solid delivery systems comprising

- polyols)
- IT Oligosaccharides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(di-, controlled-release solid delivery systems comprising polyols)
- IT Carboxylic acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(esters, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(films, controlled-release solid delivery systems comprising polyols)
- IT Neisseria meningitidis  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(group A, controlled-release solid delivery systems comprising polyols)
- IT Neisseria meningitidis  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(group B, controlled-release solid delivery systems comprising polyols)
- IT Neisseria meningitidis  
(group C, controlled-release solid delivery systems comprising polyols)
- IT Virus, animal  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(herpes, controlled-release solid delivery systems comprising polyols)
- IT Sulfates, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrogen, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(implants, controlled-release solid delivery systems comprising polyols)
- IT Lymphokines and Cytokines  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(interleukins, controlled-release solid delivery systems comprising polyols)
- IT Glycophospholipids  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lipid A, monophosphates, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(lozenges, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(microparticles, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(microspheres, controlled-release solid delivery systems comprising polyols)
- IT Headache  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(migraine, agents for the treatment of; controlled-release solid delivery systems comprising polyols)
- IT Antibodies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(monoclonal, controlled-release solid delivery systems comprising polyols)
- IT Glycopeptides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(muramic acid-contg., controlled-release solid delivery systems comprising polyols)
- IT Surfactants  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(nonionic, controlled-release solid delivery systems comprising polyols)
- IT Nucleotides, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oligo-, controlled-release solid delivery systems comprising polyols)
- IT Polyethers, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ortho ester group-contg., controlled-release solid delivery systems comprising polyols)

- IT Virus, animal  
(papilloma, controlled-release solid delivery systems comprising polyols)
- IT Vasodilators  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peripheral, controlled-release solid delivery systems comprising polyols)
- IT Alcohols, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyhydric, controlled-release solid delivery systems comprising polyols)
- IT Amino acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polymers, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(powders, controlled-release solid delivery systems comprising polyols)
- IT Virus, animal  
(respiratory syncytial, controlled-release solid delivery systems comprising polyols)
- IT Virus, animal  
(rota-, controlled-release solid delivery systems comprising polyols)
- IT Carboxylic acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(salts, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(solids, controlled-release, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(spheres, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(suppositories, controlled-release solid delivery systems comprising polyols)
- IT Pharmaceutical dosage forms  
(tablets, controlled-release solid delivery systems comprising polyols)
- IT Oligosaccharides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tri-, controlled-release solid delivery systems comprising polyols)
- IT Haemophilus influenzae  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(type b, controlled-release solid delivery systems comprising polyols)
- IT 50-99-7, Glucose, biological studies 57-50-1, biological studies 57-83-0, Progesterone, biological studies 58-22-0, Testosterone 63-42-3 69-79-4 99-20-7, Trehalose 470-55-3 512-69-6 585-86-4, Lactitol 585-88-6, Maltitol 597-12-6, Melezitose 604-68-2, .alpha.-D-Glucose pentaacetate 604-69-3, .beta.-D-Glucose pentaacetate 3616-19-1, Cellobiose octaacetate 4618-18-2, Lactulose 6424-12-0, Raffinose undecaacetate 6556-12-3D, Glucuronic acid, polymers 7208-47-1, Sorbitol hexaacetate 9003-99-0, Peroxidase 9004-10-8, Insulin, biological studies 9004-54-0, Dextran, biological studies 13718-94-0, Isomaltulose 17273-84-6, Aluminum hexanoate 17606-72-3, Maltulose 20942-99-8 25018-27-3, Trehalose octaacetate 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26680-10-4, Polylactide 26780-50-7, Poly(glycolide-lactide) 27253-33-4, Calcium neodecanoate 38954-67-5 59865-13-3, Cyclosporin a 64519-82-0, Palatinit 66112-59-2, Saf-1 66594-14-7, Quil a 102787-20-2 177327-93-4 177327-94-5 177472-68-3  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(controlled-release solid delivery systems comprising polyols)

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN  
 ACCESSION NUMBER: 1992:124367 HCAPLUS  
 DOCUMENT NUMBER: 116:124367

TITLE: Stabilization of biological macromolecular substances and other organic compounds with nonreducing polyhydroxy glycosides or oligosaccharides

INVENTOR(S): Roser, Bruce Joseph; Colaco, Camilo

PATENT ASSIGNEE(S): Quadrant Holdings Cambridge Ltd., UK

SOURCE: PCT Int. Appl., 24 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9118091	A1	19911128	WO 1991-GB759	19910514
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9178725	A1	19911210	AU 1991-78725	19910514
EP 541556	A1	19930519	EP 1991-909487	19910514
EP 541556	B1	19980916		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05508315	T2	19931125	JP 1991-509304	19910514
JP 3101320	B2	20001023		
AT 171209	E	19981015	AT 1991-909487	19910514
ES 2125237	T3	19990301	ES 1991-909487	19910514
US 5621094	A	19970415	US 1994-255565	19940608
PRIORITY APPLN. INFO.:				
			GB 1990-10742	A 19900514
			WO 1991-GB759	A 19910514
			US 1992-965384	B1 19921214

AB (Bio)org. compds. are preserved in a dry state, at elevated temps., and/or under irradsn. with nonreducing oligosaccharides or polyhydroxy glycosides. Restriction endonuclease PstI was dried at room temp. in the presence of trehalose then stored for 2 wks at 37.degree.. The enzyme retained 100% of its original activity after this treatment.

IT 13718-94-0, Isomaltulose 64519-82-0, Palatinin 50-70-4, Sorbitol, biological studies 57-50-1, Sucrose, biological studies 69-65-8, Mannitol 99-20-7, Trehalose 470-55-3, Stachyose 512-69-6, Raffinose 534-73-6 585-86-4, Lactitol 585-88-6, Maltitol 597-12-6, Melezitose 4233-70-9


RL: ANST (Analytical study)

(bioorg. compd. stabilization to drying and elevated temp. and irradsn. with)

RN 13718-94-0 HCAPLUS

CN D-Fructose, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 64519-82-0 HCAPLUS

CN D-Glucitol, 6-O-.alpha.-D-glucopyranosyl-, mixt. with 1-O-.alpha.-D-glucopyranosyl-D-mannitol (9CI) (CA INDEX NAME)

CM 1

CRN 20942-99-8  
CMF C12 H24 011


Absolute stereochemistry.



CM 2


CRN 534-73-6  
CMF C12 H24 011

Absolute stereochemistry.




RN 50-70-4 HCAPLUS  
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 57-50-1 HCAPLUS  
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 69-65-8 HCAPLUS  
CN D-Mannitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 99-20-7 HCAPLUS  
CN .alpha.-D-Glucopyranoside, .alpha.-D-glucopyranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 470-55-3 HCAPLUS  
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OH

RN 512-69-6 HCAPLUS  
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)- (9CI) (CA INDEX NAME)




Absolute stereochemistry. Rotation (+).



RN 534-73-6 HCAPLUS

CN D-Glucitol, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 585-86-4 HCAPLUS

CN D-Glucitol, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 585-88-6 HCAPLUS

CN D-Glucitol, 4-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 597-12-6 HCAPLUS

CN .alpha.-D-Glucopyranoside, O-.alpha.-D-glucopyranosyl-(1.fwdarw.3)-.beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 4233-70-9 HCAPLUS

CN D-Mannose, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 9012-36-6P, Agarose

RL: PREP (Preparation)

(gels, stabilization to drying of, nonreducing oligosaccharides and polyhydroxy glycosides in)

RN 9012-36-6 HCAPLUS

CN Agarose (8CI, 9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 9003-99-0D, Peroxidase, fusion products with Ig F(ab)2 fragment

81295-32-1, Restriction endonuclease PstI

RL: ANST (Analytical study)

(stabilization to drying of, nonreducing oligosaccharides and polyhydroxy glycosides in)

RN 9003-99-0 HCAPLUS

CN Peroxidase (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 81295-32-1 HCAPLUS

CN Nuclease, restriction endodeoxyribo-, PstI (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IC ICM C12N009-96

ICS A61K047-26

CC 9-2 (Biochemical Methods)

ST bioorg compd preservation drying temp; irradsn bioorg compd preservation;  
oligosaccharide nonreducing bioorg compd preservation; polyhydroxy  
glycoside nonreducing preservation biomol

IT Galactosides

Glycosides

Oligosaccharides

RL: ANST (Analytical study)

(nonreducing, bioorg. compd. stabilization to drying and elevated temp.  
and irradsn. with)

IT Preservation

(of org. and bioorg. compds., to drying and elevated temp. and irradsn.,  
with nonreducing polyhydroxy glycosides and oligosaccharides)

IT Temperature effects, biological

(on org. and bioorg. compds., stabilization with nonreducing  
polyhydroxy glycosides and oligosaccharides in relation to.)

IT Drying

(stabilization of org. and bioorg. compds. to, with nonreducing  
polyhydroxy glycosides and oligosaccharides)

IT Organic compounds, miscellaneous

RL: MSC (Miscellaneous)

(stabilization of, to drying and elevated temp. and irradsn., with  
nonreducing polyhydroxy glycosides and oligosaccharides)

IT Light stabilizers

(UV, nonreducing polyhydroxy glycosides and oligosaccharides  
as, for org. and bioorg. compds.)

IT Carbohydrates and Sugars, uses

RL: USES (Uses)

(alditols, nonreducing, glycosides, bioorg. compd.  
stabilization to drying and elevated temp. and irradsn. with)

IT Organic compounds, miscellaneous

RL: MSC (Miscellaneous)

(biol., stabilization of, to drying and elevated temp. and irradsn.,  
with nonreducing polyhydroxy glycosides and oligosaccharides)

IT Oligosaccharides

RL: ANST (Analytical study)

(di-, nonreducing, bioorg. compd. stabilization to drying and elevated  
temp. and irradsn. with)

IT Alcohols, uses

RL: USES (Uses)

(polyhydric, nonreducing, glycosides, bioorg. compd.  
stabilization to drying and elevated temp. and irradsn. with)

IT Phycoerythrins

RL: ANST (Analytical study)

(R-, stabilization to drying of, nonreducing oligosaccharides and  
polyhydroxy glycosides in)

IT 13718-94-0, Isomaltulose 64519-82-0, Palatinin

50-70-4, Sorbitol, biological studies 57-50-1, Sucrose,

biological studies 69-65-8, Mannitol 99-20-7,

Trehalose 470-55-3, Stachyose 512-69-6, Raffinose

534-73-6 585-86-4, Lactitol 585-88-6, Maltitol

597-12-6, Melezitose 4233-70-9

RL: ANST (Analytical study)

(bioorg. compd. stabilization to drying and elevated temp. and irradsn.  
with)

IT 9012-36-6P, Agarose

RL: PREP (Preparation)

(gels, stabilization to drying of, nonreducing oligosaccharides and polyhydroxy glycosides in)  
IT 9003-99-0D, Peroxidase, fusion products with Ig F(ab)2 fragment  
81295-32-1, Restriction endonuclease PstI  
RL: ANST (Analytical study)  
(stabilization to drying of, nonreducing oligosaccharides and polyhydroxy glycosides in)